WO2019002370A1 - Glycosaminoglycanes réticulés et fonctionnalisés - Google Patents

Glycosaminoglycanes réticulés et fonctionnalisés Download PDF

Info

Publication number
WO2019002370A1
WO2019002370A1 PCT/EP2018/067253 EP2018067253W WO2019002370A1 WO 2019002370 A1 WO2019002370 A1 WO 2019002370A1 EP 2018067253 W EP2018067253 W EP 2018067253W WO 2019002370 A1 WO2019002370 A1 WO 2019002370A1
Authority
WO
WIPO (PCT)
Prior art keywords
glycosaminoglycan
moiety
chain
crosslinked
deacetylated
Prior art date
Application number
PCT/EP2018/067253
Other languages
English (en)
Inventor
Craig Steven Harris
Johan Olsson
Original Assignee
Nestlé Skin Health Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestlé Skin Health Sa filed Critical Nestlé Skin Health Sa
Publication of WO2019002370A1 publication Critical patent/WO2019002370A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2351/00—Characterised by the use of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives of such polymers
    • C08J2351/02—Characterised by the use of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives of such polymers grafted on to polysaccharides

Definitions

  • the present invention relates to the field of hydrogels containing cross- linked polysaccharides and the use of such hydrogels in medical and/or cosmetic applications. More specifically, the present invention deals with cross-linked hyaluronic acid hydrogels modified with hydrophobic or hydrophilic side-chains.
  • hyaluronic acid is a naturally occurring polysaccharide belonging to the group of glycosaminoglycans (GAGs).
  • GAGs glycosaminoglycans
  • Hyaluronic acid and the other GAGs are negatively charged heteropolysaccharide chains which have a capacity to absorb large amounts of water.
  • Hyaluronic acid and products derived from hyaluronic acid are widely used in the biomedical and cosmetic fields, for instance during viscosurgery and as a dermal filler.
  • Water-absorbing gels are widely used in the biomedical field. They are generally prepared by chemical cross-linking of polymers to infinite networks. While native hyaluronic acid and certain cross-linked hyaluronic acid products absorb water until they are completely dissolved, cross-linked hyaluronic acid gels typically absorb a certain amount of water until they are saturated, i.e. they have a finite liquid retention capacity, or swelling degree.
  • hyaluronic acid Since hyaluronic acid is present with identical chemical structure except for its molecular mass in most living organisms, it gives a minimum of reactions and allows for advanced medical uses. Cross-linking and/or other modifications of the hyaluronic acid molecule is necessary to improve its duration in vivo. Furthermore, such modifications affect the liquid retention capacity of the hyaluronic acid molecule. As a consequence thereof, hyaluronic acid has been the subject of many modification attempts.
  • WO 01/85801 discloses a process for crosslinking polymers containing primary and secondary amine groups with activated dicarboxylic acids. An example is discussed in which hyaluronic acid is crosslinked with aspartic acid.
  • the hyaluronic acid to be crosslinked is prepared in harsh conditions leading to degradation of the hyaluronic acid, and the crosslinked hyaluronic acid fragments do not form a hydrogel but instead a solution that is filtered and then "quenched" by sulphation of the residual amino groups.
  • the present invention provides according to a first aspect thereof, a method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, said method comprising: i) providing a crosslinked glycosaminoglycan, wherein said
  • glycosaminoglycan is at least partially N-deacetylated such that the
  • crosslinked glycosaminoglycan comprises free amine groups; and ii) covalently grafting a reactive side-chain to the free amine groups of the crosslinked glycosaminoglycan, wherein the reactive side-chain comprises a functional group capable of forming a covalent bond to the free amine groups, and a side-chain moiety selected from the group consisting of a hydrophobic moiety, a charged moiety, and a peptide moiety.
  • cross-linking refers to a reaction involving sites or groups on existing macronnolecules or an interaction between existing macronnolecules that results in the formation of a small region in a macronnolecule from which at least four chains emanate.
  • a reaction of a reactive chain end of a linear macronnolecule with an internal reactive site of another linear macronnolecule results in the formation of a branch point or graft, but is not regarded as a cross-linking reaction.
  • grafting refers to a reaction in which one or more species are connected to the main chain of a macronnolecule as side- chains having constitutional or configurational features that differ from those in the main chain.
  • composition formed using the inventive method is a hydrogel. That is, it can be regarded as a water-insoluble, but substantially dilute crosslinked system of glycosaminoglycan molecules when subjected to a liquid, typically an aqueous liquid.
  • the hydrogel composition contains mostly liquid by weight and can e.g. contain 90-99.9% water, but it behaves like a solid due to a three-dimensional crosslinked hyaluronic acid network within the liquid. Due to its significant liquid content, the gel is structurally flexible and similar to natural tissue, which makes it very useful as a scaffold in tissue engineering and for tissue augmentation.
  • the hydrogel composition is preferably biocompatible. This implies that no, or only very mild, immune response occurs in the treated individual. That is, no or only very mild undesirable local or systemic effects occur in the treated individual.
  • hyaluronic acid and crosslinked hyaluronic acid products generally are inert materials when injected
  • modifying said hyaluronic acid or crosslinked hyaluronic acid with a different moieity can result in a different effect in vivo and properties of the gel.
  • This invention describes a way to modify glycosaminoglycan molecules by "capping" residual amines, formed by deacetylation of the glycosaminoglycan molecules. The capping can be performed using different functional side-chain and chemistries, resulting in different gel properties as well as potential in vivo effects.
  • the general concept for hyaluronic acid is illustrated in Scheme 1 .
  • the present invention provides a method of preparing hydrogel products with grafted side-chains in an efficient and controlled manner.
  • the method may for example be used to provide hydrogel products with tailored swelling characteristics, hydrophobicity/hydrophilicity and/or solubility.
  • Applications for hydrogels with tailored properties may for example be for use as injectable fillers for tissue aumentation or for drug delivery.
  • the capping process can be performed in aqueous or non-aqueous conditions and applied to crosslinked glycosaminoglycan hydrogels as well as polysaccharides.
  • the capping process can be performed using different types of chemistries resulting in different functional groups, typical amides, ureas, thioureas, carbamates etc.
  • Scheme 2 illustrates the concept of capping by formation of more lipophilic amides from a amide crosslinked linker-free gel with residual amines.
  • Glycosaminoglycans in their native form are N-acetylated.
  • the present invention is based on the realization that free amine groups formed by deacetylation of glycosaminoglycans can advantageously be used as graft points for attachment of functional side-chains to the glycosaminoglycan backbone.
  • the present invention has been made possible through the recent inventive realization that hydroxylamine (NH2OH) and salts thereof can advantageously be used for deacetylation of glycosaminoglycans, e.g.
  • hyaluronic acid comprising N-acetyl groups under mild reaction conditions.
  • Using hydroxylamine or a salt thereof for deacetylation has been found to allow for N-deacetylation under mild conditions resulting in only minor degradation of the polymeric backbone of sensitive polysaccharides such as HA.
  • Using hydroxylamine or a salt thereof for deacetylation thus allows for production of deacetylated HA with retained high molecular weight. This is in contrast to previously known methods, such as deacetylation using hydrazine or NaOH as the deacetylating agent, where high degrees of deacetylation have been inevitably accompanied by severe degradation of the polymeric backbone.
  • glycosaminoglycans and glycosaminoglycan hydrogels are glycosaminoglycans and glycosaminoglycan hydrogels. This means that amine functionalized hydrogels can be achieved under controlled conditions, with minimal degradation of the glycosaminoglycan network. Functional side- chains can then be grafted to the free amine groups using mild and efficient coupling techniques.
  • At least partial deacetylation as used herein as used herein with reference to the glycosaminoglycan, we mean that at least some of the N-acetyl groups of a glycosaminoglycan comprising N-acetyl groups are cleaved off, resulting in the formation of free amine groups in the glycosaminoglycan.
  • at least partial deacetylation we mean that a significant portion of the N-acetyl groups of the glycosaminoglycan, particularly at least 1 %, preferably at least 2 %, at least 3 %, at least 4 %, or at least 5 %, of the N-acetyl groups of the
  • glycosaminoglycan are converted to free amine groups. More preferably, at least 3 % of the N-acetyl groups of the glycosaminoglycan are converted to free amine groups.
  • glycosaminoglycan By the term “at least partially deacetylated” as used herein with reference to the glycosaminoglycan, we mean a glycosaminoglycan comprising N-acetyl groups in which at least some of the N-acetyl groups have been cleaved off, resulting in the formation of free amine groups in the glycosaminoglycan.
  • at least partially deacetylated we mean that a significant portion of the N-acetyl groups of the
  • glycosaminoglycan particularly at least 1 %, preferably at least 2 %, at least 3 %, at least 4 %, at least 5 %, of the N-acetyl groups of the glycosaminoglycan have been converted to free amine groups. More preferably, at least 3 % of the N-acetyl groups of the glycosaminoglycan have been converted to free amine groups.
  • the free amines can be used for mild and efficient coupling of various reactive side-chains to the glycosaminoglycan.
  • the reactive side- chain comprises a functional group capable of forming a covalent bond to the free amine, and a side-chain moiety.
  • the functional group preferably comprises a carboxylic acid or aldehyde functional group.
  • Carboxylic acid and aldehyde groups are preferred because they can readily be used, together with a suitable coupling agent, to form stable amide or secondary amine bonds together with free amine under mild reaction conditions.
  • step ii comprises covalently grafting aldehyde or carboxylic acid containing side chains to the free amine groups of the crosslinked glycosaminoglycan.
  • the side-chain moiety is selected from a hydrophobic moiety and a peptide moiety.
  • the reactive side-chain comprises a hydrophobic moiety.
  • the side-chain moiety may comprise a
  • the hydrophobic moiety comprises a linear or branched, saturated or unsaturated, C2-C22 alkyl group, preferably a linear or branched, saturated or unsaturated, C2-C12 alkyl group, preferably a linear or branched, saturated or unsaturated, C2-C6 alkyl group.
  • the reactive side-chain is a carboxylic acid selected from the group consisting of propanoic acid, butanoic acid, pentanoic acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, tetradecanoic acid, pentadecanoic acid, hexadecanoic acid, heptadecanoic acid, octadecanoic acid, nonadecanoic acid, and icosanoic acid.
  • the reactive side-chain is a carboxylic acid selected from the group consisting of propanoic acid, butanoic acid, pentanoic acid, hexanoic acid.
  • the reactive side-chain is a charged moiety, comprising one or more positively or negatively charged groups.
  • positively charged groups include, but are not limited to, amino acids such as lysine, proline and serine.
  • negatively charged groups include, but are not limited to, diacids such as malonic acid, succinic acid, adipic acid and aspartic acid.
  • the reactive side-chain is a peptide moiety.
  • peptide moieties include, but are not limited to, amino acids such as serine, cysteine, lysine, aspartic acid and leucine.
  • the reactive side-chain is a hydrophobic peptide moiety.
  • the molar ratio of the reactive side-chain to the disaccharides of the glycosaminoglycan is 0.1 -50%, preferably 1 -20% and more preferably 8-12%.
  • the crosslinked glycosaminoglycan provided in step i) is crosslinked by amide bonds.
  • the crosslinked glycosaminoglycan provided in step i) is:
  • crosslinked glycosaminoglycan formed by crosslinking an at least partially N-deacetylated glycosaminoglycan by amide bonds between carboxyl groups and free amine groups on the glycosaminoglycan backbone, wherein the crosslinked glycosaminoglycan comprises residual free amine groups;
  • crosslinked glycosaminoglycan to at least partial N-deacetylation.
  • the crosslinked glycosaminoglycan provided in step i) is crosslinked by ether bonds.
  • the glycosaminoglycan provided in step i) may have been crosslinked by a crosslinking agent selected from the group consisting of divinyl sulfone, multiepoxides and diepoxides, such as selected from the group consisting of 1 ,4-butanediol diglycidyl ether (BDDE), 1 ,2-ethanediol diglycidyl ether (EDDE) and diepoxyoctane.
  • BDDE 1,4-butanediol diglycidyl ether
  • EDDE 1 ,2-ethanediol diglycidyl ether
  • diepoxyoctane diepoxyoctane
  • i) comprises the steps: a) providing a solution comprising an at least partially deacetylated glycosaminoglycan and optionally a second glycosaminoglycan;
  • glycosaminoglycan and/or the optional second glycosaminoglycan with a coupling agent, to form activated glycosaminoglycans ;
  • glycosaminoglycans to provide glycosaminoglycans crosslinked by amide bonds.
  • the at least partially deacetylated glycosaminoglycan is selected from the group consisting of deacetylated hyaluronic acid, deacetylated chondroitin and deacetylated chondroitin sulfate, and mixtures thereof.
  • the at least partially deacetylated glycosaminoglycan is deacetylated hyaluronic acid.
  • the at least partially deacetylated glycosaminoglycan has a degree of acetylation of 99% or less, preferably 98% or less, preferably 97% or less, preferably 96% or less, preferably 95% or less, preferably 94% or less, preferably 93% or less, and a weight average molecular weight of 0.1 MDa or more, preferably 0.5 MDa or more.
  • the crosslinked glycosaminoglycan provided in step i) has a Degree of Acetylation of at least 75%, such as at least 80%, such as at least 85%, such as at least 90%.
  • the crosslinked glycosaminoglycan provided in step i) has a Degree of Acetylation between 75-99%, such as between 80- 98 %.
  • the crosslinked glycosaminoglycan provided in step ii) forms an insoluble gel network.
  • glycosaminoglycan may be in the form of a hydrogel and not be in solution.
  • the crosslinked glycosaminoglycan provided in step ii) may form an insoluble network before and/or after grafting of the reactive side-chain to the free amine groups of the crosslinked glycosaminoglycan.
  • the crosslinked glycosaminoglycan provided in step ii) may form an insoluble gel network after heat sterilization.
  • the glycosaminoglycan used for crosslinking in step i) may have a M w of above 300 kDa, such as above 400 kDa, such as above 500 kDa, such as above 700 kDa.
  • the glycosaminoglycan used for crosslinking in step i) has a viscosity of above 9.0 dl/g. This may correspond to the glycosaminoglycan having a M w of about 465 kDa.
  • the crosslinked glycosaminoglycan provided in step i) forms an insoluble gel network.
  • the insoluble gel network may have a Swelling capacity in saline (SwC) above 70 mL/g.
  • the at least partially deacetylated glycosaminoglycan is obtained by a method for at least partial deacetylation of a glycosaminoglycan, comprising: a1 ) providing a glycosaminoglycan comprising acetyl groups;
  • glycosaminoglycan comprising acetyl groups to react with hydroxylamine (NH2OH) or a salt thereof at a temperature of 100 °C or less for 2-200 hours to form an at least partially deacetylated glycosaminoglycan;
  • the second glycosaminoglycan is selected from the group consisting of hyaluronic acid, chondroitin and chondroitin sulfate, and mixtures thereof. According to some embodiments, the second glycosaminoglycan is hyaluronic acid.
  • the reactive side-chain is grafted to the free amine groups by amide bonds.
  • the grafting of step (ii) provides amide bonds between glycosaminoglycan molecules the reactive side-chains.
  • Amide bonds are stable covalent bonds that are not easily hydrolysed. Accordingly, hydrogel products according to the invention, where both crosslinking and grafting is effected by amide bonds will be less sensitive to degradation than similar products where crosslinking or grafting is effected by a weaker bond. Using the same types of bond in crosslinking and grafting may also provide a more predictable degradation behaviour of the product.
  • At least 90 % of the bonds between glycosaminoglycan molecules and the reactive side-chains are amide bonds.
  • less than 5 % of the bonds between glycosaminoglycan molecules and the reactive side-chains are ester bonds.
  • the grafting of the reactive side-chains to the free amine groups of the glycosaminoglycan molecules is preferably effected by means of a suitable coupling agent.
  • the coupling agent is a peptide coupling agent.
  • the coupling agent may for example be selected from the group consisting of triazine-based coupling agents, carbodiimide coupling agents, imidazolium-derived coupling agents, Oxyma and COMU.
  • a preferred coupling agent is a triazine-based coupling agent, including the group consisting of 4-(4,6-dimethoxy-1 ,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) and 2-chloro-4,6-dimethoxy-1 ,3,5-triazine (CDMT).
  • the coupling agent is DMTMM.
  • DMTMM/disaccharide repeating unit ratio Accordingly, the swelling of the gel product can be controlled by variation of the amount of DMTMM used.
  • the DMTMM/disaccharide repeating unit ratio is in the range of 1 -10. In some embodiments, the DMTMM/ disaccharide repeating unit ratio is in the range of 1 -3. In some embodiments, the DMTMM/ disaccharide repeating unit ratio is in the range of 1 -1 .5. In some
  • the DMTMM/ disaccharide repeating unit ratio is in the range of 3-10. In some embodiments, the DMTMM/ disaccharide repeating unit ratio is in the range of 3-8. In some embodiments, the DMTMIW disaccharide repeating unit ratio is in the range of 4-6.
  • the hydrogel product is further provided with a therapeutically relevant concentration of a local anesthetic.
  • a local anesthetic is a drug that causes reversible local anesthesia and a loss of nociception. When it is used on specific nerve pathways (nerve block), effects such as analgesia (loss of pain sensation) and paralysis (loss of muscle power) can be achieved.
  • the local anesthetic may be added to the composition to reduce pain or discomfort experienced by the patient due to the injection procedure.
  • the local anesthetic is selected from the group consisting of amide and ester type local anesthetics, for example bupivacaine, butanilicaine, carticaine, cinchocaine (dibucaine), clibucaine, ethyl parapiperidinoacetylaminobenzoate, etidocaine, lignocaine (lidocaine), mepivacaine, oxethazaine, prilocaine, ropivacaine, tolycaine, trimecaine, vadocaine, articaine, levobupivacaine, amylocaine, cocaine, propanocaine, clormecaine, cyclomethycaine, proxymetacaine, amethocaine (tetracaine), benzocaine, butacaine, butoxycaine, butyl aminobenzoate, chloroprocaine, dimethocaine (larocaine), oxybuprocaine, piperocaine, parethoxycaine
  • the preferred local anesthetic is lidocaine.
  • the local anesthetic is lidocaine.
  • Lidocaine is a well-known substance, which has been used extensively as a local anesthetic in injectable formulations, such as hyaluronic acid
  • the concentration of the amide or ester local anesthetic may be selected by the skilled person within the therapeutically relevant concentration ranges of each specific local anesthetic or a combination thereof. In some embodiments the concentration of said local anesthetic is in the range of 0.1 to 30 mg/ml. In certain embodiments the concentration of said local anesthetic is in the range of 0.5 to 10 mg/ml.
  • the lidocaine When lidocaine is used as the local anesthetic, the lidocaine may preferably be present in a concentration in the range of 1 to 5 mg/ml, more preferably in the range of 2 to 4 mg/ml, such as in a concentration of about 3 mg/ml.
  • the method described herein may further involve sterilization of the hydrogel product by autoclaving, i.e sterilization using saturated steam.
  • the hydrogel product has been subjected to sterilization by autoclaving.
  • the autoclaving may be performed at an Fo- value > 4.
  • the autoclaving may preferably be performed at an Fo-value in the range of 10 to 50.
  • the Fo value of a saturated steam sterilisation process is the lethality expressed in terms of the equivalent time in minutes at a temperature of 121 °C delivered by the process to the product in its final container with reference to microorganisms posessing a Z-value of 10.
  • the method further comprises providing particles of the hydrogel product, having an average size in the range of 0.01 -5 mm, preferably 0.1 -0.8 mm.
  • hydrogel product obtainable by the method described above.
  • a hydrogel product comprising a crosslinked glycosaminoglycan, wherein at least some of the acetyl groups of the N-acetyl glucosamine (GlcNAc) repeating units of the glycosaminoglycan have been substituted by a side- chain comprising a side-chain moiety selected from the group consisting of a hydrophobic moiety, a charged moiety, and a peptide moiety.
  • GlcNAc N-acetyl glucosamine
  • the side-chain comprises a hydrophobic moiety.
  • the hydrophobic moiety comprises a linear or branched, saturated or unsaturated, C2-C22 alkyl group, preferably a linear or branched, saturated or unsaturated, C2-C12 alkyl group, preferably a linear or branched, saturated or unsaturated, C2-C6 alkyl group.
  • the side-chain is a charged moiety, comprising one or more positively or negatively charged groups.
  • the side-chain is a peptide moiety, preferably a hydrophobic peptide moiety. In some embodiments, the side-chain is attached to the glucosamine repeating unit by an amide bond.
  • hydrogel product may be further defined as described above with reference to the method of preparing the hydrogel product.
  • the hydrogel product according to the invention may be provided in the form of a pre-filled syringe, i.e. a syringe that is pre-filled with the injectable hydrogel composition and autoclaved.
  • hydrogel product as described herein may advantageously be used for the transport or administration and slow or controlled release of various parmaceutical or cosmetic substances.
  • the hydrogel product described herein may be employed in medical as well as non-medical, e.g. purely cosmetic, procedures by injection of the composition into soft tissues of a patient or subject.
  • the compositions have been found useful in, e.g., soft tissue augmentation, for example filling of wrinkles, by hyaluronic acid gel injection.
  • the compositions have also been found useful in a cosmetic treatment, referred to herein as skin revitalization, whereby small quantities of the hyaluronic acid composition are injected into the dermis at a number of injection sites distributed over an area of the skin to be treated, resulting in improved skin tone and skin elasticity.
  • Skin revitalization whereby small quantities of the hyaluronic acid composition are injected into the dermis at a number of injection sites distributed over an area of the skin to be treated, resulting in improved skin tone and skin elasticity.
  • the hydrogel product may be useful, for example in the treatment of various dermatological conditions.
  • an hydrogel product as described above for use in a dermatological treatment selected from the group consisting of wound healing, treatment of dry skin conditions or sun-damaged skin, treatment of hyper pigmentation disorders, treatment and prevention of hair loss, and treatment of conditions that have
  • hydrogel product as described above for use in the manufacture of a medicament for use in a dermatological treatment selected from the group consisting of wound healing, treatment of dry skin conditions or sun-damaged skin, treatment of hyper pigmentation disorders, treatment and prevention of hair loss, and treatment of conditions that have inflammation as a component of the disease process, such as psoriasis and asteototic eczema.
  • a hydrogel product as described above for cosmetic, non-medical, treatment of a subject by injection of the composition into the skin of the subject may be for improving the appearance of the skin, preventing and/or treating hair loss, filling wrinkles or contouring the face or body of a subject.
  • the cosmetic, nonmedical, use does not involve treatment of any form of disease or medical condition. Examples of improving the appearance of the skin include, but are not limited to, treatment of sun-damaged or aged skin, skin revitalization, skin whitening and treatment of hyper pigmentation disorders such as senile freckles, melasma and ephelides.
  • hydrogel product as described herein for use as a medicament.
  • cosmetically treating skin which comprises administering to the skin a hydrogel product as described herein.
  • FIG. 1 shows the experimental results summarized from Example 3.
  • SwC - Swelling capacity in saline total liquid uptake per gram PS (mL/g).
  • GelP - Gel part is a description of the percentage of PS that is a part of the gel network.
  • a number of 90% means that 10% of the polysaccharide is not a part of the gel network.
  • DoA Degree of Acetylation.
  • the degree of acetylation is the molar ratio of acetyl groups compared to hyaluronic acid disaccharides.
  • DoA can be calculated from NMR spectra by comparing the integral of the acetyl signal of the hyaluronan disaccharide residues to the integral of the C2-H signal of the deacetylated glucosamine residues according to the equation. Integral acetylgroup
  • DoA (%) Integral acetylgroup * 100
  • the coupling agent DMTMM was dissolved in Na-phosphate buffer (pH 7.4), and pH was controlled and adjusted if necessary. The DMTMM solution was subsequently added to deacetylated HA. The suspension was homogenized by shaking for 3.5 minutes and mixing with a spatula. The reaction mixture was placed in an incubator at 23 °C for 24 hours. The reaction was stopped by removal from the incubator and the gel was pressed through a 1 mm steel mesh two times followed by addition of 0.25 M NaOH to the resulting material (pH >13) and mixed for 60 minutes and subsequently neutralized with 1 .2 M HCI.
  • BDDE (1 .8 mol%/HA) and 1 % NaOH was mixed and added to hyaluronan (1 000 kDa).
  • the sample was mixed and incubated in 23 °C for 24 h.
  • the resulting material was cut in to pieces and swelled in diluted acid to obtain neutral pH.
  • the gel was particle size reduced through a 125 m mesh, precipitated in ethanol, washed with ethanol (70 w/w%) and dried in vacuum overnight to obtain a white powder (GelP 87%; SwCC 36 mL/g)
  • the carboxylate side-chain (1 equiv./HA disaccharide), is dissolved in acetonitrile. Then, /V-hydroxysulfosuccinimide sodium salt (1 equiv./HA disaccharide) dissolved in water is added dropwise under stirring at 23 °C, followed by dropwise addition of A/-(3-dimethylaminopropyl)- A/'(ethylcarbodiimide hydrochloride solution in water. The reaction mixture is stirred for 15 hours and subsequently neutralized with 0.25 M NaOH. Thereafter, the precipitated gel powder (from example 5) is added to the reaction mixture and continued to stir at 23 °C for 15 hours.
  • the gel suspension pH is controlled and adjusted to 7.0-7.5 if necessary. After neutralization, the gel is precipitated in EtOH and washed with 70 w/w% EtOH + 100 mM NaCI (1x), 70 w/w% EtOH (1 x) followed by EtOH (2x) and dried in vacuum over night.
  • the experimental setup is presented in Table 6. Table 6.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un procédé de préparation d'un produit hydrogel comprenant des molécules de glycosaminoglycane réticulé, ledit procédé consistant à : i) fournir un glycosaminoglycane réticulé, ledit glycosaminoglycane étant au moins partiellement N-désacétylé de telle sorte que le glycosaminoglycane réticulé comprend des groupes amine libres ; et ii) greffer de manière covalente une chaîne latérale réactive aux groupes amine libres du glycosaminoglycane réticulé, la chaîne latérale réactive comprenant un groupe fonctionnel apte à former une liaison covalente avec les groupes amine libres, et un fragment de chaîne latérale sélectionné dans le groupe constitué par un fragment hydrophobe, un fragment chargé et un fragment peptidique. L'invention concerne également un produit hydrogel comprenant un glycosaminoglycane réticulé, au moins certains des groupes acétyle de la N-acétyl-glucosamine (GlcNAc) des unités répétitives du glycosaminoglycane ayant été substituées par une chaîne latérale comprenant un fragment de chaîne latérale sélectionné dans le groupe constitué par un fragment hydrophobe, un fragment chargé et un fragment peptidique.
PCT/EP2018/067253 2017-06-28 2018-06-27 Glycosaminoglycanes réticulés et fonctionnalisés WO2019002370A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17178478.8 2017-06-28
EP17178478 2017-06-28

Publications (1)

Publication Number Publication Date
WO2019002370A1 true WO2019002370A1 (fr) 2019-01-03

Family

ID=59350622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/067253 WO2019002370A1 (fr) 2017-06-28 2018-06-27 Glycosaminoglycanes réticulés et fonctionnalisés

Country Status (1)

Country Link
WO (1) WO2019002370A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3659632A1 (fr) * 2018-11-29 2020-06-03 Nestlé Skin Health SA Dégradation partielle post-réticulation d'hydrogels d'amide réticulés
WO2021111303A1 (fr) * 2019-12-02 2021-06-10 Galderma Holding SA Compositions esthétiques de poids moléculaire élevé
US11530301B2 (en) 2015-12-29 2022-12-20 Galderma Holding SA Carbohydrate crosslinker

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045335A1 (fr) * 1997-04-04 1998-10-15 Fidia Advanced Biopolymers, S.R.L. Composes d'acide hyaluronique n-sulfates, leurs derives et leur procede de preparation
WO2001085801A1 (fr) 2000-05-10 2001-11-15 Aquisitio S.P.A. Polymeres reticules pour des utilisations pharmaceutiques, medicales et cosmetiques
US20070053987A1 (en) * 2005-09-02 2007-03-08 Thomas Bayer Cross-linked polysacharide and protein matrices and methods for their preparation
EP3252082A1 (fr) * 2016-05-31 2017-12-06 Galderma S.A. Procédé pour la désacétylation de biopolymères
EP3252081A1 (fr) * 2016-05-31 2017-12-06 Galderma S.A. Hydrolyse de liaisons esters de glycosaminoglycanes réticulés par des liaisons amides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045335A1 (fr) * 1997-04-04 1998-10-15 Fidia Advanced Biopolymers, S.R.L. Composes d'acide hyaluronique n-sulfates, leurs derives et leur procede de preparation
WO2001085801A1 (fr) 2000-05-10 2001-11-15 Aquisitio S.P.A. Polymeres reticules pour des utilisations pharmaceutiques, medicales et cosmetiques
US20070053987A1 (en) * 2005-09-02 2007-03-08 Thomas Bayer Cross-linked polysacharide and protein matrices and methods for their preparation
EP3252082A1 (fr) * 2016-05-31 2017-12-06 Galderma S.A. Procédé pour la désacétylation de biopolymères
EP3252081A1 (fr) * 2016-05-31 2017-12-06 Galderma S.A. Hydrolyse de liaisons esters de glycosaminoglycanes réticulés par des liaisons amides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Industrial Biotechnological Polymers", 1 January 1995, TECHNOMIC PUBL, article TAKEHIKO WADA ET AL: "Synthesis of Hyaluronan Derivatives Containing Nucleic Acid Bases", pages: 121 - 157, XP055504565 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11530301B2 (en) 2015-12-29 2022-12-20 Galderma Holding SA Carbohydrate crosslinker
US11643509B2 (en) 2015-12-29 2023-05-09 Galderma Holding SA Carbohydrate crosslinker
US11708461B2 (en) 2015-12-29 2023-07-25 Galderma Holding SA Method for preparing acylated crosslinked glycosaminoglycans
US11780970B2 (en) 2015-12-29 2023-10-10 Galderma Holding S.A. Carbohydrate crosslinker
US11939433B2 (en) 2015-12-29 2024-03-26 Galderma Holding S.A. Method for preparing acylated crosslinked glycosaminoglycans
EP3659632A1 (fr) * 2018-11-29 2020-06-03 Nestlé Skin Health SA Dégradation partielle post-réticulation d'hydrogels d'amide réticulés
WO2020110007A1 (fr) * 2018-11-29 2020-06-04 Nestlé Skin Health S.A. Dégradation partielle post-réticulation d'hydrogels réticulés à l'aide d'un amide
WO2021111303A1 (fr) * 2019-12-02 2021-06-10 Galderma Holding SA Compositions esthétiques de poids moléculaire élevé
CN115335414A (zh) * 2019-12-02 2022-11-11 高德美控股有限公司 高分子量美容组合物
US11730691B2 (en) 2019-12-02 2023-08-22 Galderma Holding SA High molecular weight esthetic compositions
CN115335414B (zh) * 2019-12-02 2024-03-19 高德美控股有限公司 高分子量美容组合物

Similar Documents

Publication Publication Date Title
US10131718B2 (en) Cross-linked hyaluronic acid grafted with dextran
EP3520827B1 (fr) Hydrogels réticulés pour l'augmentation des tissus mous
JP6479783B2 (ja) 架橋ヒアルロン酸生成物を調製するための方法
WO2019002368A1 (fr) Glycosaminoglycanes réticulés et fonctionnalisés
US20210308332A1 (en) Hydrogel compositions encapsulating solid particles
EP3302591B1 (fr) Hydrogels mélangés d'acide hyaluronique et de dextrane
WO2019002370A1 (fr) Glycosaminoglycanes réticulés et fonctionnalisés
TW202041221A (zh) 修飾透明質酸衍生物及其製備方法、其應用、其用途、交聯的水凝膠及其製備方法、用於原位形成其之套組
US20230346680A1 (en) High molecular weight esthetic compositions
WO2019002369A1 (fr) Hydrogel de glycosaminoglycane avec dextrane ou cyclodextrine greffé
WO2019001784A1 (fr) Gel d'acide hyaluronique avec un cation divalent
US10898613B2 (en) Hyaluronic acid gel with a divalent zinc cation
US20200140626A1 (en) Method of preparing a hydrogel product
TW202317214A (zh) 以絲蛋白交聯多醣及所得材料之用途
US20210284759A1 (en) Post-crosslinking partial degradation of amide crosslinked hydrogels
WO2019002371A1 (fr) Gel de glycosaminoglycane avec tampon bis-tris
WO2023148619A1 (fr) Procédés de production d'hydrogels à base acide hyaluronique réticulés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18734804

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18734804

Country of ref document: EP

Kind code of ref document: A1